Boryung Corporation (003850.KS)
KRW 10260.0
(-3.39%)
KRW 10260.0
(-3.39%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 333.26 Billion KRW | 8.49% |
| 2022 | 307.18 Billion KRW | 15.95% |
| 2021 | 264.93 Billion KRW | 14.47% |
| 2020 | 231.44 Billion KRW | 3.79% |
| 2019 | 222.99 Billion KRW | 18.23% |
| 2018 | 188.61 Billion KRW | 12.39% |
| 2017 | 167.81 Billion KRW | -4.98% |
| 2016 | 176.6 Billion KRW | 4.51% |
| 2015 | 168.98 Billion KRW | 5.51% |
| 2014 | 160.16 Billion KRW | 13.66% |
| 2013 | 140.92 Billion KRW | 11.54% |
| 2012 | 126.34 Billion KRW | -0.02% |
| 2011 | 126.36 Billion KRW | 4.4% |
| 2010 | 121.03 Billion KRW | 11.45% |
| 2009 | 108.6 Billion KRW | 14.08% |
| 2008 | 95.19 Billion KRW | -4.12% |
| 2007 | 99.27 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 89.57 Billion KRW | 6.86% |
| 2024 Q3 | 271.03 Billion KRW | 1.87% |
| 2024 Q1 | 83.82 Billion KRW | -14.21% |
| 2023 Q4 | 97.71 Billion KRW | 18.93% |
| 2023 Q1 | 79.32 Billion KRW | 1.92% |
| 2023 Q3 | 82.15 Billion KRW | -7.83% |
| 2023 FY | 333.26 Billion KRW | 8.49% |
| 2023 Q2 | 89.14 Billion KRW | 12.37% |
| 2022 Q2 | 76.23 Billion KRW | -0.18% |
| 2022 FY | 307.18 Billion KRW | 15.95% |
| 2022 Q4 | 77.83 Billion KRW | 1.42% |
| 2022 Q3 | 76.73 Billion KRW | 0.66% |
| 2022 Q1 | 76.37 Billion KRW | 15.0% |
| 2021 Q2 | 62.57 Billion KRW | -4.74% |
| 2021 Q1 | 65.68 Billion KRW | 12.79% |
| 2021 FY | 264.93 Billion KRW | 14.47% |
| 2021 Q3 | 70.26 Billion KRW | 12.3% |
| 2021 Q4 | 66.41 Billion KRW | -5.49% |
| 2020 Q1 | 54.33 Billion KRW | -3.55% |
| 2020 FY | 231.44 Billion KRW | 3.79% |
| 2020 Q3 | 61.81 Billion KRW | 8.32% |
| 2020 Q4 | 58.23 Billion KRW | -5.79% |
| 2020 Q2 | 57.06 Billion KRW | 5.03% |
| 2019 Q2 | 56.52 Billion KRW | 11.13% |
| 2019 FY | 222.99 Billion KRW | 18.23% |
| 2019 Q1 | 50.86 Billion KRW | 21.34% |
| 2019 Q3 | 59.28 Billion KRW | 4.88% |
| 2019 Q4 | 56.32 Billion KRW | -4.98% |
| 2018 Q4 | 41.91 Billion KRW | -15.56% |
| 2018 Q3 | 49.64 Billion KRW | -2.4% |
| 2018 FY | 188.61 Billion KRW | 12.39% |
| 2018 Q2 | 50.86 Billion KRW | 10.11% |
| 2018 Q1 | 46.19 Billion KRW | 13.82% |
| 2017 Q3 | 42.45 Billion KRW | -2.87% |
| 2017 Q4 | 40.58 Billion KRW | -4.4% |
| 2017 FY | 167.81 Billion KRW | -4.98% |
| 2017 Q1 | 41.07 Billion KRW | 4.63% |
| 2017 Q2 | 43.7 Billion KRW | 6.4% |
| 2016 FY | 176.6 Billion KRW | 4.51% |
| 2016 Q2 | 50.28 Billion KRW | 24.41% |
| 2016 Q3 | 46.65 Billion KRW | -7.22% |
| 2016 Q4 | 39.25 Billion KRW | -15.85% |
| 2016 Q1 | 40.41 Billion KRW | -14.9% |
| 2015 Q4 | 47.49 Billion KRW | 13.86% |
| 2015 Q2 | 42.84 Billion KRW | 16.0% |
| 2015 Q1 | 36.93 Billion KRW | -17.73% |
| 2015 FY | 168.98 Billion KRW | 5.51% |
| 2015 Q3 | 41.71 Billion KRW | -2.64% |
| 2014 Q1 | 35.37 Billion KRW | -10.61% |
| 2014 Q3 | 39.84 Billion KRW | -0.52% |
| 2014 Q4 | 44.89 Billion KRW | 12.69% |
| 2014 Q2 | 40.05 Billion KRW | 13.21% |
| 2014 FY | 160.16 Billion KRW | 13.66% |
| 2013 Q2 | 38.9 Billion KRW | 41.67% |
| 2013 Q4 | 39.57 Billion KRW | 13.14% |
| 2013 FY | 140.92 Billion KRW | 11.54% |
| 2013 Q1 | 27.46 Billion KRW | -7.76% |
| 2013 Q3 | 34.98 Billion KRW | -10.08% |
| 2012 FY | 126.34 Billion KRW | -0.02% |
| 2012 Q1 | 33.03 Billion KRW | 18.15% |
| 2012 Q4 | 29.77 Billion KRW | -7.78% |
| 2012 Q3 | 32.28 Billion KRW | 3.31% |
| 2012 Q2 | 31.25 Billion KRW | -5.4% |
| 2011 Q4 | 27.96 Billion KRW | -10.28% |
| 2011 FY | 126.36 Billion KRW | 4.4% |
| 2011 Q3 | 31.16 Billion KRW | -7.9% |
| 2011 Q2 | 33.83 Billion KRW | 1.29% |
| 2011 Q1 | 33.4 Billion KRW | 27.84% |
| 2010 Q2 | 33.96 Billion KRW | 14.34% |
| 2010 Q1 | 29.7 Billion KRW | 9.61% |
| 2010 FY | 121.03 Billion KRW | 11.45% |
| 2010 Q4 | 26.13 Billion KRW | -16.36% |
| 2010 Q3 | 31.24 Billion KRW | -8.01% |
| 2009 Q3 | 25.5 Billion KRW | -11.72% |
| 2009 Q1 | 27.1 Billion KRW | 20.33% |
| 2009 Q2 | 28.89 Billion KRW | 6.59% |
| 2009 Q4 | 27.09 Billion KRW | 6.25% |
| 2009 FY | 108.6 Billion KRW | 14.08% |
| 2008 Q4 | 22.52 Billion KRW | -2.85% |
| 2008 Q1 | 24.41 Billion KRW | -6.16% |
| 2008 Q2 | 25.06 Billion KRW | 2.69% |
| 2008 FY | 95.19 Billion KRW | -4.12% |
| 2008 Q3 | 23.18 Billion KRW | -7.5% |
| 2007 FY | 99.27 Billion KRW | 0.0% |
| 2007 Q2 | 23.94 Billion KRW | 1.36% |
| 2007 Q4 | 26.01 Billion KRW | 1.26% |
| 2007 Q1 | 23.62 Billion KRW | 0.0% |
| 2007 Q3 | 25.69 Billion KRW | 7.28% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -616.63% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 8.47% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -67.567% |
| HANDOK Inc. | 151.36 Billion KRW | -120.174% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -395.755% |
| Yuhan Corporation | 564.5 Billion KRW | 40.963% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | -3.432% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -1303.412% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 60.128% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -344.125% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -67.504% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -719.858% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -252.608% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -136.603% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -616.63% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -859.993% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -333.841% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 2866.727% |
| JW Holdings Corporation | 446.15 Billion KRW | 25.302% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | -60.582% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 49.146% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 0.716% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -323.9% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -342.953% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -361.518% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -81.307% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -616.63% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | -12.927% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 51.101% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 0.716% |
| Yuhan Corporation | 564.5 Billion KRW | 40.963% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | -65.13% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -369.796% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -236.543% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 0.716% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -128.436% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -92.099% |
| CKD Bio Corp. | 5.01 Billion KRW | -6551.679% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | -31.089% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -81.002% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -239.636% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -323.9% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 10.29% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -565.932% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -67.504% |
| JW Lifescience Corporation | 51.32 Billion KRW | -549.331% |